Vr Adviser, LLC Aerovate Therapeutics, Inc. Transaction History

Vr Adviser, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$19.17 - $27.7 $1.65 Million - $2.38 Million	86,058 Added 11.51%	833,927 $16.8 Million
Q4 2022 May 15, 2023	SELL	$15.92 - $30.52 $1.37 Million - $2.63 Million	-86,058 Reduced 10.32%	747,869 $21.9 Million
Q4 2022 Feb 14, 2023	SELL	$15.92 - $30.52 $1.37 Million - $2.63 Million	-86,058 Reduced 10.32%	747,869 $21.9 Million
Q3 2022 May 15, 2023	BUY	$14.77 - $25.79 $3.6 Million - $6.28 Million	243,519 Added 41.25%	833,927 $13.8 Million
Q3 2022 Nov 14, 2022	BUY	$14.77 - $25.79 $3.6 Million - $6.28 Million	243,519 Added 41.25%	833,927 $13.8 Million
Q2 2022 May 15, 2023	SELL	$10.8 - $16.91 $1.7 Million - $2.66 Million	-157,461 Reduced 21.05%	590,408 $9.23 Million
Q2 2022 Aug 15, 2022	BUY	$10.8 - $16.91 $4.75 Million - $7.43 Million	439,371 Added 290.9%	590,408 $9.23 Million
Q1 2022 May 16, 2022	BUY	$8.25 - $18.33 $1.25 Million - $2.77 Million	151,037 New	151,037 $2.77 Million

28.1M

116K

26.6K

Ticker AVTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,448,100
Market Cap $64.3M
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...

Get notified when there are updates to the investment portfolio of Vr Adviser, LLC, based on Form 13F filings with the SEC.

Stay updated on Vr Adviser, LLC with notifications on news.